• 00:23 1.
    index 1
  • 01:16 2.
    Title
  • 01:36 3.
    About Breast Cancer
  • 00:52 4.
    Triple Negative Breast Cancer Subtype
  • 01:06 5.
    FUSCC TNBC Subtype
  • 01:05 6.
    FUSCC TNBC Subtype
  • 01:00 7.
    Luminal Androgen Receptor LAR
  • 00:47 8.
    Immunomodulatory IM
  • 01:12 9.
    Basal-like Immune-suppressed BLIS
  • 00:51 10.
    Mesenchymal-like MES
  • 00:49 11.
    FUTURE clinical trial
  • 00:43 12.
    Slide 12
  • 01:38 13.
    Metabolic Dysregulation in TNBCs
  • 00:55 14.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 01:10 15.
    Metabolic-Pathway-Based Stratification of TNBC
  • 01:20 16.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:32 17.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 01:04 18.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 01:23 19.
    Slide 20
  • 00:51 20.
    The Metabolomic Landscape of TNBC
  • 01:37 21.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 01:18 22.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 01:05 23.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 00:34 24.
    Slide 26
  • 00:55 25.
    Ferroptosis
  • 00:48 26.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 01:02 27.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 00:36 28.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 01:16 29.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 01:02 30.
    Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
  • 00:34 31.
    Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
  • 00:57 32.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 01:09 33.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 00:39 34.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 01:19 35.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 01:36 36.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 01:19 37.
    GPX4 Inhibitors Diminish Tumor Growth In Vivo
  • 00:59 38.
    Slide 40
  • 00:53 39.
    Slide 41
  • 04:54 40.
    Slide 40
  • 00:10 41.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:37 42.
    The Metabolomic Landscape of TNBC
  • 01:10 43.
    Metabolic-Pathway-Based Stratification of TNBC
  • 03:22 44.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 00:17 45.
    Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
  • 00:01 46.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 00:00 47.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 00:00 48.
    Ferroptosis
  • 00:00 49.
    Slide 26
  • 04:28 50.
    Ferroptosis
  • 00:36 51.
    About Breast Cancer
  • 00:02 52.
    ** after 1112seminar.pptx
  • 00:01 53.
    About Breast Cancer
  • 00:00 54.
    Triple Negative Breast Cancer Subtype
  • 00:00 55.
    FUSCC TNBC Subtype
  • 00:00 56.
    FUSCC TNBC Subtype
  • 00:00 57.
    Luminal Androgen Receptor LAR
  • 00:01 58.
    Immunomodulatory IM
  • 00:00 59.
    Basal-like Immune-suppressed BLIS
  • 00:00 60.
    Mesenchymal-like MES
  • 00:00 61.
    Basal-like Immune-suppressed BLIS
  • 00:03 62.
    Immunomodulatory IM
  • 00:00 63.
    Luminal Androgen Receptor LAR
  • 00:00 64.
    FUSCC TNBC Subtype
  • 00:00 65.
    Luminal Androgen Receptor LAR
  • 00:00 66.
    Immunomodulatory IM
  • 00:00 67.
    Basal-like Immune-suppressed BLIS
  • 00:00 68.
    Mesenchymal-like MES
  • 00:00 69.
    Basal-like Immune-suppressed BLIS
  • 00:00 70.
    Immunomodulatory IM
  • 00:39 71.
    Luminal Androgen Receptor LAR
  • 00:01 72.
    Immunomodulatory IM
  • 00:00 73.
    Basal-like Immune-suppressed BLIS
  • 00:01 74.
    Mesenchymal-like MES
  • 00:01 75.
    FUTURE clinical trial
  • 00:01 76.
    Slide 12
  • 00:02 77.
    Metabolic Dysregulation in TNBCs
  • 00:07 78.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 00:03 79.
    Metabolic Dysregulation in TNBCs
  • 00:47 80.
    About Breast Cancer
  • 00:00 81.
    Triple Negative Breast Cancer Subtype
  • 00:23 82.
    FUSCC TNBC Subtype
  • 00:00 83.
    FUSCC TNBC Subtype
  • 00:00 84.
    Luminal Androgen Receptor LAR
  • 00:00 85.
    Immunomodulatory IM
  • 00:00 86.
    Basal-like Immune-suppressed BLIS
  • 00:00 87.
    Mesenchymal-like MES
  • 02:10 88.
    FUTURE clinical trial
  • 00:07 89.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:01 90.
    Metabolic-Pathway-Based Stratification of TNBC
  • 00:06 91.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:04 92.
    Metabolic-Pathway-Based Stratification of TNBC
  • 02:30 93.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:02 94.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:57 95.
    The Metabolomic Landscape of TNBC
  • 00:01 96.
    Slide 20
  • 00:04 97.
    The Metabolomic Landscape of TNBC
  • 00:02 98.
    Slide 20
  • 00:27 99.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:01 100.
    The Metabolomic Landscape of TNBC
  • 00:00 101.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:00 102.
    The Metabolomic Landscape of TNBC
  • 00:07 103.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:00 104.
    The Metabolomic Landscape of TNBC
  • 00:06 105.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:09 106.
    The Metabolomic Landscape of TNBC
  • 00:00 107.
    Polar Metabolite and Lipid Profiling of TNBC
  • 00:00 108.
    Slide 20
  • 00:00 109.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 110.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 111.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:16 112.
    Metabolic-Pathway-Based Stratification of TNBC
  • 00:08 113.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 00:27 114.
    Metabolic-Pathway-Based Stratification of TNBC
  • 00:00 115.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 00:00 116.
    Metabolic Dysregulation in TNBCs
  • 00:00 117.
    Slide 12
  • 00:00 118.
    FUTURE clinical trial
  • 00:16 119.
    Slide 12
  • 00:00 120.
    Metabolic Dysregulation in TNBCs
  • 00:00 121.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 00:59 122.
    Metabolic-Pathway-Based Stratification of TNBC
  • 01:42 123.
    NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
  • 00:07 124.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 00:01 125.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 00:15 126.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 00:01 127.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 00:00 128.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 01:58 129.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 01:05 130.
    Slide 40
  • 01:57 131.
    Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
  • 00:07 132.
    FUSCC TNBC Subtype
  • 00:00 133.
    Luminal Androgen Receptor LAR
  • 00:01 134.
    Immunomodulatory IM
  • 00:00 135.
    Basal-like Immune-suppressed BLIS
  • 00:01 136.
    Mesenchymal-like MES
  • 00:28 137.
    FUTURE clinical trial
  • 00:00 138.
    Mesenchymal-like MES
  • 00:00 139.
    Basal-like Immune-suppressed BLIS
  • 00:00 140.
    Immunomodulatory IM
  • 00:00 141.
    Luminal Androgen Receptor LAR
  • 00:00 142.
    FUSCC TNBC Subtype
  • 00:00 143.
    FUSCC TNBC Subtype
  • 00:00 144.
    Triple Negative Breast Cancer Subtype
  • 00:01 145.
    About Breast Cancer
  • 00:18 146.
    Title
  • 00:10 147.
    About Breast Cancer
  • 00:01 148.
    Triple Negative Breast Cancer Subtype
  • 00:02 149.
    FUSCC TNBC Subtype
  • 00:48 150.
    Triple Negative Breast Cancer Subtype
  • 00:55 151.
    FUSCC TNBC Subtype
  • 00:28 152.
    FUSCC TNBC Subtype
  • 00:24 153.
    Luminal Androgen Receptor LAR
  • 00:00 154.
    Immunomodulatory IM
  • 00:36 155.
    Basal-like Immune-suppressed BLIS
  • 00:23 156.
    Mesenchymal-like MES
  • 00:18 157.
    FUTURE clinical trial
  • 00:35 158.
    Slide 12
  • 00:00 159.
    Metabolic Dysregulation in TNBCs
  • 00:00 160.
    Estimation of the Optimal Clustering Numbers of TNBC Subtypes
  • 00:31 161.
    Metabolic-Pathway-Based Stratification of TNBC
  • 00:00 162.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:01 163.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:30 164.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 165.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:07 166.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:19 167.
    Slide 20
  • 00:01 168.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 169.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 170.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:00 171.
    Metabolic-Pathway-Based Stratification of TNBC
  • 01:46 172.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:01 173.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:05 174.
    Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
  • 00:05 175.
    Slide 26
  • 00:41 176.
    Ferroptosis
  • 00:33 177.
    AR is the key regulator of GPX4 expression in LAR tumors
  • 00:00 178.
    AR Binds to the GPX4 Promoter and Drives its Expression
  • 00:00 179.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 01:26 180.
    Targeting GPX4 is a Better Strategy than Targeting AR for Patients
  • 00:53 181.
    Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
  • 05:46 182.
    GPX4 Inhibitors Diminish Tumor Growth In Vivo
  • 00:07 183.
    ** after 1112seminar.pptx
  • Index
  • Notes
  • Comment
  • Fullscreen
20230220 lab meeting_家銘 (no sound)
Duration: 1:34:08, Browse: 59, Last Updated: 2023-05-16
    Prev Next
    • 00:23 1.
      index 1
    • 01:16 2.
      Title
    • 01:36 3.
      About Breast Cancer
    • 00:52 4.
      Triple Negative Breast Cancer Subtype
    • 01:06 5.
      FUSCC TNBC Subtype
    • 01:05 6.
      FUSCC TNBC Subtype
    • 01:00 7.
      Luminal Androgen Receptor LAR
    • 00:47 8.
      Immunomodulatory IM
    • 01:12 9.
      Basal-like Immune-suppressed BLIS
    • 00:51 10.
      Mesenchymal-like MES
    • 00:49 11.
      FUTURE clinical trial
    • 00:43 12.
      Slide 12
    • 01:38 13.
      Metabolic Dysregulation in TNBCs
    • 00:55 14.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 01:10 15.
      Metabolic-Pathway-Based Stratification of TNBC
    • 01:20 16.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:32 17.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 01:04 18.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 01:23 19.
      Slide 20
    • 00:51 20.
      The Metabolomic Landscape of TNBC
    • 01:37 21.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 01:18 22.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 01:05 23.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 00:34 24.
      Slide 26
    • 00:55 25.
      Ferroptosis
    • 00:48 26.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 01:02 27.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 00:36 28.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 01:16 29.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 01:02 30.
      Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
    • 00:34 31.
      Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
    • 00:57 32.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 01:09 33.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 00:39 34.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 01:19 35.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 01:36 36.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 01:19 37.
      GPX4 Inhibitors Diminish Tumor Growth In Vivo
    • 00:59 38.
      Slide 40
    • 00:53 39.
      Slide 41
    • 04:54 40.
      Slide 40
    • 00:10 41.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:37 42.
      The Metabolomic Landscape of TNBC
    • 01:10 43.
      Metabolic-Pathway-Based Stratification of TNBC
    • 03:22 44.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 00:17 45.
      Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
    • 00:01 46.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 00:00 47.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 00:00 48.
      Ferroptosis
    • 00:00 49.
      Slide 26
    • 04:28 50.
      Ferroptosis
    • 00:36 51.
      About Breast Cancer
    • 00:02 52.
      ** after 1112seminar.pptx
    • 00:01 53.
      About Breast Cancer
    • 00:00 54.
      Triple Negative Breast Cancer Subtype
    • 00:00 55.
      FUSCC TNBC Subtype
    • 00:00 56.
      FUSCC TNBC Subtype
    • 00:00 57.
      Luminal Androgen Receptor LAR
    • 00:01 58.
      Immunomodulatory IM
    • 00:00 59.
      Basal-like Immune-suppressed BLIS
    • 00:00 60.
      Mesenchymal-like MES
    • 00:00 61.
      Basal-like Immune-suppressed BLIS
    • 00:03 62.
      Immunomodulatory IM
    • 00:00 63.
      Luminal Androgen Receptor LAR
    • 00:00 64.
      FUSCC TNBC Subtype
    • 00:00 65.
      Luminal Androgen Receptor LAR
    • 00:00 66.
      Immunomodulatory IM
    • 00:00 67.
      Basal-like Immune-suppressed BLIS
    • 00:00 68.
      Mesenchymal-like MES
    • 00:00 69.
      Basal-like Immune-suppressed BLIS
    • 00:00 70.
      Immunomodulatory IM
    • 00:39 71.
      Luminal Androgen Receptor LAR
    • 00:01 72.
      Immunomodulatory IM
    • 00:00 73.
      Basal-like Immune-suppressed BLIS
    • 00:01 74.
      Mesenchymal-like MES
    • 00:01 75.
      FUTURE clinical trial
    • 00:01 76.
      Slide 12
    • 00:02 77.
      Metabolic Dysregulation in TNBCs
    • 00:07 78.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 00:03 79.
      Metabolic Dysregulation in TNBCs
    • 00:47 80.
      About Breast Cancer
    • 00:00 81.
      Triple Negative Breast Cancer Subtype
    • 00:23 82.
      FUSCC TNBC Subtype
    • 00:00 83.
      FUSCC TNBC Subtype
    • 00:00 84.
      Luminal Androgen Receptor LAR
    • 00:00 85.
      Immunomodulatory IM
    • 00:00 86.
      Basal-like Immune-suppressed BLIS
    • 00:00 87.
      Mesenchymal-like MES
    • 02:10 88.
      FUTURE clinical trial
    • 00:07 89.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:01 90.
      Metabolic-Pathway-Based Stratification of TNBC
    • 00:06 91.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:04 92.
      Metabolic-Pathway-Based Stratification of TNBC
    • 02:30 93.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:02 94.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:57 95.
      The Metabolomic Landscape of TNBC
    • 00:01 96.
      Slide 20
    • 00:04 97.
      The Metabolomic Landscape of TNBC
    • 00:02 98.
      Slide 20
    • 00:27 99.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:01 100.
      The Metabolomic Landscape of TNBC
    • 00:00 101.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:00 102.
      The Metabolomic Landscape of TNBC
    • 00:07 103.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:00 104.
      The Metabolomic Landscape of TNBC
    • 00:06 105.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:09 106.
      The Metabolomic Landscape of TNBC
    • 00:00 107.
      Polar Metabolite and Lipid Profiling of TNBC
    • 00:00 108.
      Slide 20
    • 00:00 109.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 110.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 111.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:16 112.
      Metabolic-Pathway-Based Stratification of TNBC
    • 00:08 113.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 00:27 114.
      Metabolic-Pathway-Based Stratification of TNBC
    • 00:00 115.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 00:00 116.
      Metabolic Dysregulation in TNBCs
    • 00:00 117.
      Slide 12
    • 00:00 118.
      FUTURE clinical trial
    • 00:16 119.
      Slide 12
    • 00:00 120.
      Metabolic Dysregulation in TNBCs
    • 00:00 121.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 00:59 122.
      Metabolic-Pathway-Based Stratification of TNBC
    • 01:42 123.
      NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
    • 00:07 124.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 00:01 125.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 00:15 126.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 00:01 127.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 00:00 128.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 01:58 129.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 01:05 130.
      Slide 40
    • 01:57 131.
      Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
    • 00:07 132.
      FUSCC TNBC Subtype
    • 00:00 133.
      Luminal Androgen Receptor LAR
    • 00:01 134.
      Immunomodulatory IM
    • 00:00 135.
      Basal-like Immune-suppressed BLIS
    • 00:01 136.
      Mesenchymal-like MES
    • 00:28 137.
      FUTURE clinical trial
    • 00:00 138.
      Mesenchymal-like MES
    • 00:00 139.
      Basal-like Immune-suppressed BLIS
    • 00:00 140.
      Immunomodulatory IM
    • 00:00 141.
      Luminal Androgen Receptor LAR
    • 00:00 142.
      FUSCC TNBC Subtype
    • 00:00 143.
      FUSCC TNBC Subtype
    • 00:00 144.
      Triple Negative Breast Cancer Subtype
    • 00:01 145.
      About Breast Cancer
    • 00:18 146.
      Title
    • 00:10 147.
      About Breast Cancer
    • 00:01 148.
      Triple Negative Breast Cancer Subtype
    • 00:02 149.
      FUSCC TNBC Subtype
    • 00:48 150.
      Triple Negative Breast Cancer Subtype
    • 00:55 151.
      FUSCC TNBC Subtype
    • 00:28 152.
      FUSCC TNBC Subtype
    • 00:24 153.
      Luminal Androgen Receptor LAR
    • 00:00 154.
      Immunomodulatory IM
    • 00:36 155.
      Basal-like Immune-suppressed BLIS
    • 00:23 156.
      Mesenchymal-like MES
    • 00:18 157.
      FUTURE clinical trial
    • 00:35 158.
      Slide 12
    • 00:00 159.
      Metabolic Dysregulation in TNBCs
    • 00:00 160.
      Estimation of the Optimal Clustering Numbers of TNBC Subtypes
    • 00:31 161.
      Metabolic-Pathway-Based Stratification of TNBC
    • 00:00 162.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:01 163.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:30 164.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 165.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:07 166.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:19 167.
      Slide 20
    • 00:01 168.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 169.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 170.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:00 171.
      Metabolic-Pathway-Based Stratification of TNBC
    • 01:46 172.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:01 173.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:05 174.
      Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
    • 00:05 175.
      Slide 26
    • 00:41 176.
      Ferroptosis
    • 00:33 177.
      AR is the key regulator of GPX4 expression in LAR tumors
    • 00:00 178.
      AR Binds to the GPX4 Promoter and Drives its Expression
    • 00:00 179.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 01:26 180.
      Targeting GPX4 is a Better Strategy than Targeting AR for Patients
    • 00:53 181.
      Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
    • 05:46 182.
      GPX4 Inhibitors Diminish Tumor Growth In Vivo
    • 00:07 183.
      ** after 1112seminar.pptx
    Location
    1. Media Center
    2. ...
    3. 2023
    Folder name
    2023
    Author
    黃照穎
    Branch
    賴亮全教授
    Created
    2023-04-17 09:01:51
    Last Updated
    2023-05-16 16:29:40
    Browse
    59
    Duration
    1:34:08

    臺北市仁愛路一段1號10樓1009室

    R1009 10F No1 Sec1 Ren-Ai Rd, Taipei 100233, Taiwan.

    E-mail: llai@ntu.edu.tw

    Tel: 886-2-2312-3456 # 288241

    Lab: 886-2-2393-8235